Drugs & Therapy Perspectives

, Volume 20, Issue 8, pp 12–15 | Cite as

‘Pay attention’ to stimulants in attention-deficit hyperactivity disorder when other psychiatric disorders exist

Disease Management


  1. 1.
    Pliszka SR. Psychiatric comorbidities in children with attention deficit hyperactivity disorder. Implications for management. Pediatr Drugs 2003; 5(11): 741–50CrossRefGoogle Scholar
  2. 2.
    MTA Cooperative Group. Moderators and mediators of treatment response for children with attention deficit hyperactivity disorder: the MTA study. Arch Gen Psychiatry 1999; 56: 1088–96CrossRefGoogle Scholar
  3. 3.
    Swanson J. Compliance with stimulants for attention-deficit/ hyperactivity disorder. Issues and approaches for improvement. CNS Drugs 2003; 17(2): 117–31PubMedCrossRefGoogle Scholar
  4. 4.
    Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41: 1026–36PubMedCrossRefGoogle Scholar
  5. 5.
    Dunbar F, Kusumakar V, Daneman D, et al. Growth and sexual maturation in children are unaffected by long term treatment with risperidone. 49th meeting of the American Academy of Child and Adolescent Psychiatry; 2002 Oct 22–27; San FranciscoGoogle Scholar
  6. 6.
    Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989; 28: 882–7PubMedCrossRefGoogle Scholar
  7. 7.
    MTA Cooperative Group. 14 month randomized clinical trial of treatment strategies for children with attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999; 56(12): 1073–86CrossRefGoogle Scholar
  8. 8.
    Medicines and Healthcare Products Regulatory Agency. Safety review of antidepressants used by children completed (reference 2003/0505) [online]. Available from URL: http://www.mhra.gov.uk/news/ssri_101203.htm [Accessed 2004 Jun 21]
  9. 9.
    US Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant medications [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm [Accessed 2004 Jun 21]
  10. 10.
    Hughes CL, Emslie GJ, Crimson ML, et al. The Texas children’s medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 1999; 38(11): 1442–54PubMedCrossRefGoogle Scholar
  11. 11.
    Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–72PubMedCrossRefGoogle Scholar
  12. 12.
    Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001; 40: 307–14PubMedCrossRefGoogle Scholar
  13. 13.
    Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit-hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896–901PubMedCrossRefGoogle Scholar
  14. 14.
    Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention deficit-hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: 1–9CrossRefGoogle Scholar
  15. 15.
    Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40(10): 753–72PubMedCrossRefGoogle Scholar
  16. 16.
    Sherman M, Hauser GC, Glover BH. Toxic reactions to tranylcypromine. Am J Psychiatry 1964: 120: 1019–21PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations